Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting… Read More
Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and… Read More
VANCOUVER, B.C. — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) a publicly listed biotechnology company discovering and developing novel cancer fighting drugs in the field of immuno-oncology, announced… Read More
17 abstracts from across the Company’s portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data… Read More
Vancouver, BC and Cincinnati, OH — A newly published study in Cognitive Behaviour Therapy has found that eSense™, a digital therapy platform for women’s sexual health, is effective in treating Sexual Interest/Arousal Disorder (SIAD)… Read More
